

```

=> s methionine
    96237 METHIONINE
    554 METHIONINES
L1    96430 METHIONINE
        (METHIONINE OR METHIONINES)

=> s peroxide
    236997 PEROXIDE
    49580 PEROXIDES
L2    256595 PEROXIDE
        (PEROXIDE OR PEROXIDES)

=> s PVP or polyvinylpyrrolidone or (poly vinylpyrrolidone) or (polyvinyl
pyrrolidone) or (poly vinyl pyrrolidone)
    15020 PVP
    45 PVPS
    15040 PVP
        (PVP OR PVPS)
    19846 POLYVINYLPIRROLIDONE
    107 POLYVINYLPIRROLIDONES
    19890 POLYVINYLPIRROLIDONE
        (POLYVINYLPIRROLIDONE OR POLYVINYLPIRROLIDONES)
    752990 POLY
    2 POLIES
    752991 POLY
        (POLY OR POLIES)
    17412 VINYLPIRROLIDONE
    63 VINYLPIRROLIDONES
    17437 VINYLPIRROLIDONE
        (VINYLPIRROLIDONE OR VINYLPIRROLIDONES)
    8160 POLY VINYLPIRROLIDONE
        (POLY(W)VINYLPIRROLIDONE)
    108917 POLYVINYL
    176 POLYVINYLS
    109039 POLYVINYL
        (POLYVINYL OR POLYVINYLS)
    26126 PYRROLIDONE
    775 PYRROLIDONES
    26372 PYRROLIDONE
        (PYRROLIDONE OR PYRROLIDONES)
    3529 POLYVINYL PYRROLIDONE
        (POLYVINYL(W)PYRROLIDONE)
    752990 POLY
    2 POLIES
    752991 POLY
        (POLY OR POLIES)
    438187 VINYL
    607 VINYLS
    438363 VINYL
        (VINYL OR VINYLS)
    26126 PYRROLIDONE
    775 PYRROLIDONES
    26372 PYRROLIDONE
        (PYRROLIDONE OR PYRROLIDONES)
    2218 POLY VINYL PYRROLIDONE
        (POLY(W)VINYL(W)PYRROLIDONE)
L3    38278 PVP OR POLYVINYLPIRROLIDONE OR (POLY VINYLPIRROLIDONE) OR (POLYV
        INYL PYRROLIDONE) OR (POLY VINYL PYRROLIDONE)

```

=> s 11 and 12 and 13
L4 11 L1 AND L2 AND L3

=> d ti 1-11

L4 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
TI Pharmaceutical and cosmetic foams containing PEG and PEG derivatives and solvents and gelling agents

L4 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
TI Poly-vinylpyrrolidone electrospun composites and bio-composite sensing materials

L4 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
TI Luminoi chemiluminescence catalysed by colloidal platinum nanoparticles

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
TI Self-decontaminating surface coatings comprising polymer

L4 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
TI Vinylpyrrolidone polymer aqueous solutions and their manufacture

L4 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
TI Foamable alcohol compositions, systems and methods of use

L4 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
TI Nonaqueous single phase vehicles and formulations utilizing such vehicles

L4 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
TI Electrospun enzyme-nanocomposite biosensor

L4 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
TI Non-aqueous formulations containing biodegradable polymers and methionine and solvents for removing peroxides and reducing the oxidative degradation of drugs

L4 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
TI Monitoring of sterilant apparatus and method for monitoring sterilant

L4 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
TI Monitoring of sterilant apparatus and method for monitoring sterilant

=> d ibib abs 9

L4 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1310054 CAPLUS <LOGINID::20081030>
DOCUMENT NUMBER: 144:57512
TITLE: Non-aqueous formulations containing biodegradable polymers and methionine and solvents for removing peroxides and reducing the oxidative degradation of drugs
INVENTOR(S): Fereira, Pamela J.; Desjardin, Michael A.; Rohloff, Catherine M.; Berry, Stephen A.; Zlatkova-Karaslavova, Ekaterina S.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 36 pp., Cont.-in-part of U.S. Ser. No. 814,826.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050276856	A1	20051215	US 2005-183477	20050718
US 20050008661	A1	20050113	US 2004-814826	20040331
WO 2006083950	A2	20060810	WO 2006-US3524	20060201
WO 2006083950	A3	20061123		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2006210560	A1	20060810	AU 2006-210560	20060203
CA 2596860	A1	20060810	CA 2006-2596860	20060203
WO 2006084140	A2	20060810	WO 2006-US3858	20060203
WO 2006084140	A3	20070111		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1843747	A2	20071017	EP 2006-720234	20060203
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
JP 2008528699	T	20080731	JP 2007-554244	20060203
NO 2007004476	A	20071102	NO 2007-4476	20070903
PRIORITY APPLN. INFO.:			US 2003-459300P	P 20030331
			US 2004-814826	A2 20040331
			US 2005-650252P	P 20050203
			US 2005-183477	A 20050718
			WO 2006-US3858	W 20060203

AB The present invention is related to materials and methods for forming polymeric delivery vehicles that reduces risk of oxidative degradation of a carried drug and the resulting compns. For example, stability of ω-IFN was improved by adding L-methionine into PVP to remove peroxides.

L4 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:193693 CAPLUS <<LOGINID:20081030>>
 DOCUMENT NUMBER: 146:230149
 TITLE: Vinylpyrrolidone polymer aqueous solutions and their manufacture
 INVENTOR(S): Miyai, Takashi; Nakajima, Mitsuru
 PATENT ASSIGNEE(S): Nippon Shokubai Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 16pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2007045853	A	20070222	JP 2005-228563	20050805

PRIORITY APPLN. INFO.: JP 2005-228563 20050805
 AB In manufacture of vinylpyrrolidone polymer aqueous solns. by steps containing polymerization of N-vinylpyrrolidone (I)-based monomers in aqueous media in the presence of H₂O₂, metal catalysts, and ammonia, singlet O quenchers are allowed to exist in the reaction system in the polymerization step. Alternatively, nonvolatile organic bases are added to the polymer aqueous solns. Title solns. contain ≤2000 ppm HCO₂H and do not contain organic polymerization initiators and/or their decomposed products. Storage of aqueous solns. containing vinylpyrrolidone polymers, HCO₂H, and ammonia by the use of singlet O quenchers, and vinylpyrrolidone polymers, useful for cosmetics, pharmaceuticals, dispersing agents, and additives in filter manufacture, prepared by heat-drying the aqueous solns., are also claimed. Thus, 450 parts I was polymerized in H₂O containing Cu sulfate 0.00023, methionine 4.5, 25% NH₄OH 3.6, and 30% H₂O₂ 19.2 parts to give a 50% aqueous polyvinylpyrrolidone solution containing 1100 ppm HCO₂H and 2000 ppm ammonia. The solution was dried at 150° to give polyvinylpyrrolidone without gelation.

d his

(FILE 'HOME' ENTERED AT 15:37:07 ON 30 OCT 2008)

FILE 'CAPLUS' ENTERED AT 15:37:20 ON 30 OCT 2008

L1 96430 S METHIONINE
 L2 256595 S PEROXIDE
 L3 38278 S PVP OR POLYVINYLPIRROLIDONE OR (POLY VINYLPIRROLIDONE) OR (PO
 L4 11 S L1 AND L2 AND L3
 L5 8500 S PEROXIDE (3A) (VALUE OR LEVEL)
 L6 96430 S METHIONINE
 L7 69 S L5(L) L6
 L8 1636762 S POLYMER
 L9 0 S L7 AND L8
 L10 51 S L7 AND PY<2004

=> s l3 (L) 15

L11 2 L3 (L) L5

=> d ibib abs

L11 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1999:742417 CAPLUS <<LOGINID:20081030>>
 DOCUMENT NUMBER: 132:69146
 TITLE: Developing an injectable formula containing an oxygen-sensitive drug: a case study of danofloxacin injectable
 AUTHOR(S): Kasraian, Kasra; Kuzniar, Anna A.; Wilson, Gabrielle G.; Wood, Julia A.
 CORPORATE SOURCE: Pfizer Central Research, Groton, CT, 06340, USA
 SOURCE: Pharmaceutical Development and Technology (1999), 4(4), 475-480
 CODEN: PDTEFS; ISSN: 1083-7450
 PUBLISHER: Marcel Dekker, Inc.
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 AB A review with 10 refs. The purpose of this study was to assess the impact of impurities in formulation components, antioxidants, formulation pH, and processing/packaging on the extent of color change associated with oxidation of danofloxacin injectable. The methods used in this study include reversed-phase HPLC, UV/VIS spectrophotometry, atomic absorption spectroscopy, visual observation, and iodometric titration for quantification of the antioxidant. The results from this study revealed that trace impurities from 2 different excipients significantly contributed to color change associated with oxidation PVP introduced trace levels of peroxides into the solution A second excipient also had a significant impact on stability because it introduced trace metal impurities into the product. The minimization of oxygen levels alone in the solution and headspace was not sufficient to completely eliminate the product instability. The addition of an antioxidant, monothioglycerol (MTG), resulted in a formulation less sensitive to processing variables. The impact of pH on the performance of MTG was also studied. At pH 7.5, MTG resulted in significant improvement in stability; however, at pH 6.0 it was not effective as an antioxidant. Process modifications alone may not be sufficient to prevent oxidation Chemical approaches, such as pH control, addition of an antioxidant, and control of components should be considered first as means of enhancing stability of oxygen-sensitive solns.
 REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs 2

L11 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1976:400898 CAPLUS <<LOGINID:20081030>>
 DOCUMENT NUMBER: 85:898
 ORIGINAL REFERENCE NO.: 85:163a,166a
 TITLE: Effect of silica on lipid peroxidation in the red cells
 AUTHOR(S): Gabor, Silvia; Anca, Zoe
 CORPORATE SOURCE: Inst. Public Health Med. Res., Cluj, Rom.
 SOURCE: Internationales Archiv fuer Arbeitsmedizin (1974), 32(4), 327-32
 CODEN: IAAANS; ISSN: 0020-5923
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Five varieties of silica [7631-86-9] dust induced a significantly higher level of lipid peroxides in erythrocytes in vitro than was found in control samples. The hemolysis produced by silica dusts was associated with the formation of an appreciable amount of malonaldehyde,

indicating peroxidative cleavage of the polyunsatd. fatty acids. Pretreatment of the dusts with polyvinylpyridine N-oxide (PVP N-oxide) [9045-81-2] prevented any enhancement of lipid peroxidase [9003-99-0] activity. PVP N-oxide may act as a radical-trapping agent, blocking at the quartz surface the putative free radicals involved in the initiation of lipid peroxidn. induced by the dusts. The results obtained suggest that lipid peroxidn. of membrane-bound polyunsatd. fatty acids may be involved in the cytotoxic activity of silica dust. The damaging effect of silica dust on cells is discussed in the light of the theory of electron catalysis and in terms of damage to membranes by free radicals.